PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy.
about
Efficient drug delivery of Paclitaxel glycoside: a novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparationLong-Circulating Curcumin-Loaded Liposome Formulations with High Incorporation Efficiency, Stability and Anticancer Activity towards Pancreatic Adenocarcinoma Cell Lines In VitroPeptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivoA MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancerModification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancerApplication of liposomes in drug development--focus on gastroenterological targets.Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.Paclitaxel Nano-Delivery Systems: A Comprehensive Review.Development and In Vitro Evaluation of Liposomes Using Soy Lecithin to Encapsulate Paclitaxel.Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs.Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy.Recent advances in liposome surface modification for oral drug delivery.Encapsulated paclitaxel nanoparticles exhibit enhanced anti-tumor efficacy in A549 non-small lung cancer cells.Liposomal formulation for co-delivery of paclitaxel and lapatinib, preparation, characterization and optimization.Prussian Blue Derived Nanoporous Iron Oxides as Anticancer Drug Carriers for Magnetic-Guided Chemotherapy.PEGylated nanostructured lipid carriers (PEG-NLC) as a novel drug delivery system for biochanin A.Plasma stable, pH-sensitive fusogenic polymer-modified liposomes: A promising carrier for mitoxantrone.Plasma stable, pH-sensitive non-ionic surfactant vesicles simultaneously enhance antiproliferative effect and selectivity of Sirolimus.Noncovalent interaction-assisted drug delivery system with highly efficient uptake and release of paclitaxel for anticancer therapy.Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system.Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins.Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.RNA-based micelles: A novel platform for chemotherapeutic drug loading and delivery.Polyarginine and PEG-AEYLR comodified nanostructured lipid carrier: 10mol% uncleavable PEG-AEYLR showed no shielding effect to polyarginine in vitro while maintaining good tumor targeting in vivo.Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles.A lyophilized sterically stabilized liposome-containing docetaxel: in vitro and in vivo evaluation.Docetaxel–trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.Encapsulation of paclitaxel in ultra-fine nanoparticles of acrylic/styrene terpolymer for controlled releaseComputed Tomography-Guided Screening of Surfactant Effect on Blood Circulation Time of Emulsions: Application to the Design of an Emulsion Formulation for Paclitaxel
P2860
Q28543361-8DA4937B-D7C1-409F-B2FE-777821A68621Q28554939-9A045A5E-BEAC-4B94-A2BD-A34503DC5C25Q28728340-450BEA98-3185-4000-93AD-EFA7320454BFQ36255138-6304B236-9311-4310-9CF4-06E7EBF076C6Q36277841-CFEBE46E-C5EE-45D9-BEAD-B09EA4E164E7Q36468079-66717EA0-051F-4D87-892C-11FDC2B72BD3Q36758275-E9724DC9-0AD3-4F9B-8BE0-97E03732205BQ37119643-F5F24BE7-9DDA-420B-926F-423A5472F27EQ37250009-F00D2471-CC02-4623-91A4-F409767BDC69Q37694185-2F990C22-8015-4AE3-BB2B-60CB0B18B6A5Q38406190-B1DFA294-382C-4D19-AD5A-E7DDAF25C53EQ38789551-4DD0CEFC-6A30-4D1F-887E-6182B7117A7DQ38807276-B35CCBD4-A998-47A0-850F-41EC31FDB788Q38822833-4F278107-DC91-488E-AC8C-6A2DCEA34BACQ38844243-696DB6C1-86DA-424E-8075-6FAD596E177CQ38878745-970B2A93-E4A0-461F-A1BA-94A2E9B3A8ECQ38976681-F1A5318C-C906-4E0F-95AC-F2DB033E5F51Q39043619-4146B32F-F251-497F-A64A-D944A3027B67Q39058091-F0379491-AA03-43BC-8E00-E88EBEB56149Q42283138-0A55A24C-8735-40B9-B3B7-ABFC92BC6AFEQ42620815-8304CE44-6B70-4F75-80A0-CCEE13A71B26Q44304922-FFB79429-AB18-41FA-8EF7-CCCA76807B46Q47621457-63ABE0C5-8A41-40DA-ADCB-30A8B800E840Q49904261-3AA5F3E2-D758-4B98-89FE-E43B888DF877Q50765370-4E217775-990B-447C-9772-17A0B780BBDBQ51749858-4C5E743C-90B1-4B2C-A3D5-2475037C8D50Q53133237-AF1BC3B5-6C76-406B-8FED-60685BAF4E0EQ55285429-8A8D553E-82A5-446A-A827-1C56BEC9809AQ57347386-98EE5D4F-C3F6-4AF6-8058-326BCD3C0392Q59115809-134A3955-88D2-4336-B1CF-8107B3D1446A
P2860
PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
PEG liposomalization of paclit ...... ition and anti-tumor efficacy.
@en
PEG liposomalization of paclit ...... ition and anti-tumor efficacy.
@nl
type
label
PEG liposomalization of paclit ...... ition and anti-tumor efficacy.
@en
PEG liposomalization of paclit ...... ition and anti-tumor efficacy.
@nl
prefLabel
PEG liposomalization of paclit ...... ition and anti-tumor efficacy.
@en
PEG liposomalization of paclit ...... ition and anti-tumor efficacy.
@nl
P2093
P1476
PEG liposomalization of paclit ...... ition and anti-tumor efficacy.
@en
P2093
Kazutaka Higaki
Ken-ichi Ogawara
Toshikiro Kimura
Yusuke Kono
Yuta Yoshizawa
P304
P356
10.1016/J.IJPHARM.2011.04.008
P407
P577
2011-04-12T00:00:00Z